Puma Biotechnology: Funding, Investors & Team (Oct 2026)
Puma Biotechnology, Inc., is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB-272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer.
Puma Biotechnology has raised $10.0M across 1 funding round on record, the most recent a Post-IPO Equity of $10.0M announced in Mar 2022.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Puma Biotechnology Company Profile and Key Stats
Latest funding round on record: Mar 2022.
Puma Biotechnology Funding Rounds
Puma Biotechnology Founders and Leadership Team
Contact details for the Puma Biotechnology team: 1 of 1 has an email address on file.
Start 14-day free trial →Puma Biotechnology Funding Compared to Other Biotechnology Startups
Puma Biotechnology's latest round of $10.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Puma Biotechnology in Biotechnology and Los Angeles
Companies Similar to Puma Biotechnology
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Puma Biotechnology Funding FAQs
What does Puma Biotechnology do?
Puma Biotechnology, Inc., is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB-272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer.
How much funding has Puma Biotechnology raised?
Puma Biotechnology has raised $10.0M across 1 round on record. The most recent is a Post-IPO Equity of $10.0M announced in Mar 2022.
When did Puma Biotechnology last raise funding?
Puma Biotechnology's most recent funding round on record is a Post-IPO Equity of $10.0M, announced in Mar 2022.
Who is the CEO of Puma Biotechnology?
Alan Auerbach is listed as CEO at Puma Biotechnology.
Where is Puma Biotechnology headquartered?
Puma Biotechnology is based in Los Angeles, California, United States.
How many employees does Puma Biotechnology have?
Puma Biotechnology is in the 251-500 employee band.
How does Puma Biotechnology's funding compare to other Biotechnology startups?
Puma Biotechnology's latest round of $10.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Puma Biotechnology Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Puma Biotechnology is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.